Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

China’s Hepatitis B Market to Double by 2012

publication date: Aug 29, 2008

The market for hepatitis B drugs in China is expected to grow 135% by 2012, according to a new report from Decision Resources. From $340 million in 2007, sales of hepatitis B treatments will increase to $800 million over the five years, a CAGR of 18%. Part of the reason behind the high dollar value of drugs for this population is that the nucleoside/nucleotide analogue class of drugs often used to treat the disease must be given long term, often for the rest of a patient’s life. More details...

Stock Symbols: (NYSE: BMY) (VX: ROG) (NYSE: SGP) (NYSE: GSK)



Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here

BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here

Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here